SAB Biotherapeutics Inc Dossier
Qualitative Analysis
Business overview
SAB Biotherapeutics, Inc. (SABS) is a clinical-stage biopharmaceutical company pioneering a new class of human polyclonal immunotherapeutic antibodies. The company's proprietary DiversitAb™ platform leverages genetically engineered transchromosomic (Tc) Bovine™—cattle carrying a human artificial chromosome—to produce diverse, high-potency, fully human immunoglobulin G (hIgG) antibodies at commercial scale without relying on human donors or convalescent plasma. SAB's primary clinical focus is its lead asset, SAB-142, a potentially disease-modifying, redosable human anti-thymocyte immunoglobulin (hATG) designed to delay the onset and arrest the progression of Stage 3 autoimmune type 1 diabetes (T1D) by protecting insulin-producing pancreatic beta cells.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead product candidate, SAB-142 (a fully human anti-thymocyte immunoglobulin), through the registrational Phase 2b SAFEGUARD clinical trial for the treatment of Stage 3 new-onset Type 1 Diabetes.
Expected impact: Establish SAB-142 as a best-in-class, disease-modifying, and redosable immunotherapy that delays the progression of Type 1 Diabetes.
Refocusing the company's proprietary DiversitAb platform and transchromosomic (Tc) Bovine technology almost exclusively on immune and autoimmune disorders, specifically Type 1 Diabetes, while moving away from broad infectious disease government contracts.
Expected impact: Streamline operating expenses, optimize manufacturing processes, and maximize the commercial potential of the core polyclonal antibody platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Sanofi participated as a strategic investor in SAB's $175 million private placement. This investment provides strong validation for SAB-142's immunomodulation approach from the owner of Tzield, the only currently approved drug in the T1D delay space.
Terms: Sanofi participated alongside top-tier institutional investors in the July 2025 oversubscribed private placement, which raised $175 million upfront with potential for up to $284 million in additional proceeds through milestone-based warrants.
Secured to support the clinical manufacturing and development scale-up of SAB-142 for Type 1 Diabetes.
Terms: The agreement includes a minimum aggregate spend of $36 million following any FDA approval, with the overall multi-year agreement valued at approximately $50 million.